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A major goal of the transplant field is to tolerize donor T
cells to prevent graft-versus-host disease (GVHD) (1). We
describe an ex vivo approach in which the blockade of
CD40 ligand (CD40L:CD154):CD40 interactions, a path-





 T cells to become tolerant to host alloantigens (2).
High doses of tolerized cells did not cause GVHD lethality
in vivo. T cells had intact responses to antigens not present
during tolerization. Tolerance was long lived and not
readily reversible in vivo. These data have significant impli-
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 is a major cause of mor-
bidity and mortality after bone marrow transplantation. Op-
tions for GVHD prevention have included rigorous T cell de-
pletion ex vivo or prolonged in vivo immunosuppression (1).
Both predispose the recipient to an extended period of poor
immune reconstitution. Because a small fraction of donor T
cells respond to host alloantigens and cause GVHD, a strategy
in which GVHD-causing T cells are selectively inhibited is de-
sirable (3).
Although T cells that receive sufficient signals via the T cell
receptor (TCR) are induced to proliferate, a sustained re-
sponse requires a second (costimulatory) signal (4). Jenkins
and Schwartz demonstrated that antigen-specific T cell clones
combined with paraformaldehyde-fixed antigen-presenting
cells and antigen become incapable of responding to antigen
but are fully responsive to IL-2, a state termed anergy (4).
Paraformaldehyde-fixation prevents the cell surface expres-
sion of molecules that provide a costimulatory signal to re-
sponding T cells.
Several APC surface determinants have been shown to be
capable of providing T cell costimulation. CD40, a 50-kD
member of the nerve growth factor/tumor necrosis factor re-
ceptor family, is expressed on classical nonprofessional and
professional antigen-presenting cells (5). The T cell counter-
receptor for CD40 is CD40L, a type II integral membrane gly-











(6). CD40L transduces a signal to CD40-expressing B cells to
upregulate molecules involved in T cell costimulation (7). T
cells are tolerized when exposed to antigen in a situation
whereby APC are incapable of receiving a CD40 signal either
due to anti-CD40L mAb or a genetic deficiency of CD40 (8,
9). In vivo blockade of CD40L:CD40 interaction in rodents
has been shown to be effective in inhibiting the humoral and
cellular inflammatory responses in autoimmune mice and
recipients of solid organ or lymphohematopoietic allografts
(7–12).
Despite the ability of investigators to tolerize T cell clones,
there are no reported studies in which permanent alloantigen-
specific hyporesponsiveness has been achieved by an ex vivo
approach culminating in the prevention of GVHD in vivo in
the absence of supplemental immune suppression. The present





 T cell costimulation via disrupting the binding of
CD40L to CD40 would induce a state of alloantigen-specific










/KhEg (termed bm12) and C57BL/6-scid/scid




) mice were pur-









) mice were purchased from the National In-





 10 generations onto a BALB/c background, were gener-
ated as described and provided by Marc Jenkins (University of
Minnesota, Minneapolis, MN) (13, 14). Donors and recipients were
8–10 wk of age at the time of BMT. All mice were housed in a specific
pathogen-free facility in microisolator cages.
 
B.R. Blazar and P.A. Taylor contributed equally to this work.
Address correspondence to Bruce R. Blazar, Box 109 Mayo Bldg.,
University of Minnesota Hospital, 420 SE Delaware Street, Minneap-
olis, MN 55455; Phone: 612-626-2734; FAX: 612-624-3913; E-mail:
blaza001@maroon.tc.umn.edu
 





 Abbreviations used in this paper:
 
 CD40L, CD40 ligand; GVHD,
graft-versus-host disease; MLR, mixed lymphocyte reaction; OVA,
chicken egg ovalbumin; SCID, severe combined immunodeficient;













T cells, single cell suspensions of axillary, mesenteric, and inguinal
lymph node cells were mashed, passed through a wire mesh, and col-
lected into phosphate-buffered saline supplemented with 2% fetal
calf sera. Cell preparations were depleted of NK cells (hybridoma




T cells by coating with anti-CD8 mAb (hybridoma 2.43, rat IgG2b,
provided by David Sachs, Cambridge, MA), followed by passage
through a goat anti–mouse and goat anti–rat Ig coated column (Bio-
tex, Edmonton, Canada). The goat anti–mouse Ig coated column also
removes most Fc receptor bearing cells including B cells, macro-
phages, and dendritic cells. The final composition of T cells in the do-









 T cells. Responders were mixed with irradiated (30
Gray) anti-Thy1.2 mAb (hybridoma 30H-12, rat IgG2b, provided by
D. Sachs), and anti-NK1.1 (hybridoma PK136, mouse IgG2a, pro-
vided by G. Koo) plus complement-treated splenocyte stimulators.















 T cells at a ratio of 3:1 and then mixed with
C57BL/6 splenic stimulator cells. Responders and stimulator cells











plates (Costar, Acton, MA) containing DME (Bio Whittaker, Walk-













 M) (Sigma Chemical Co., St. Louis, MO), 10
mM Hepes buffer, 1 mM sodium pyruvate (GIBCO BRL, Grand Is-












-asparagine) (Sigma Chemical Co.), antibiotics (peni-
cillin: 100 U/ml, streptomycin: 100 mg/ml) (Sigma Chemical Co.).
Anti-CD40L mAb (hybridoma MR1, hamster IgG [6]) was obtained
by culturing the hybridoma in media with 10% fetal bovine serum in




, Cellex Biosciences, Minneapo-
lis, MN), supernatant purified by ammonium sulfate precipitation.













for 8 or 10 d. On day 5, the culture was fed 1:1 with new medium in-
cluding mAb. In some experiments, human recombinant IL-7 (R & D
Systems, Minneapolis, MN) was added at 0.1 ng/ml to support cell re-
covery. To monitor primary MLR proliferation, 96-well round bot-









 stimulator cells per well in the presence or absence of exoge-
nous IL-2 (50 IU/ml).




















 irradiated (30 Gray) non–T cell depleted
splenic stimulators were plated in the presence or absence of IL-2 (50

















splenic feeder cells for plating in 96-well microtiter plates. Chicken
egg ovalbumin (OVA) peptide 323–339 (ISQAVHAAHAEINE-









Ci) for 16–18 h be-
fore harvesting and counted in the absence of scintillation fluid on a
betaplate reader. Three to six wells were analyzed for each data
point.
 
GVH induction and IL-2 administration.
 
bm12 recipients were
sublethally irradiated by exposing mice to 6.0 Gray total body irradia-




Cesium source at a dose rate of 85 cGy/min. Day 10
MLR–cultured cells were injected intravenously at the doses indi-
cated. Hematocrit values were obtained at periodic intervals as an in-
dicator of the possible bone marrow destructive effects of infused T
cells (12, 15). Where indicated, exogenous IL-2 (AMGEN, Thousand
Oaks, CA) was administered intraperitoneally once daily at a dose
of 50,000 IU on Monday through Friday from days 0–14 of T cell
transfer.
 
T cell transfer into syngeneic SCID recipients and thoracic duct
cannulation. 
 
Control or anti-CD40L mAb–treated MLR bulk–cul-














cells into non-irradiated B6-SCID recipients as a means of examining




 T cells in vivo in the absence of alloantigen.
For thoracic duct lymphocyte isolation, cannulae were inserted in the
thoracic duct of recipients on day 40 after transfer and cells were col-
lected over a period of 18 h (12, 16). The number and phenotype of
thoracic duct lymphocytes were quantified. Thoracic duct lympho-
cytes were adoptively transferred into sublethally irradiated second-








 T cells per mouse via intra-




T cells from bulk MLR cultures and thoracic
duct lymphocytes were assessed for evidence of activation by for-
ward- and side-scatter profiles and for the co-expression of CD4 and
activation antigens including IL2R alpha chain (CD25). To distin-









 T cell population spe-





(14). KJ1–26 mAb does not detect normal BALB/c T cells. All stud-
ies were performed with two or three color flow cytometry using fluo-
rescein isothiocyanate, phycoerythrin, or biotin-conjugated mAb
(PharMingen, San Diego, CA) along with SA-PerCP (Becton Dickin-
son, Mountain View, CA). Irrelevant mAb control values were sub-
tracted from values obtained with relevant mAbs. Cultured cells were
also examined for the incorporation of 7-AAD (7-amino-actinomycin
D) (Sigma Chemical Co.). Cells with intact membranes exclude 7-AAD,
which binds to DNA; thus, 7-AAD is an early marker for apoptosis
(17). All results were obtained using a FACScalibur (Becton Dickin-
son). Forward- and side-scatter settings were gated to exclude debris.









vival data were analyzed by lifetable methods and actuarial survival



















T cells are induced into a state of alloantigen hyporespon-
siveness by prolonged ex vivo CD40L:CD40 blockade.
 
To de-
termine whether blockade of CD40L:CD40 interaction during
a mixed lymphocyte reaction (MLR) culture would induce al-




lymph node T cells were reacted with irradiated, T cell de-
pleted MHC class II disparate splenic stimulators in bulk cul-
tures in the presence or absence of anti-CD40L mAb for a pe-
riod of 10 d. MLR cultures were established with B6
responders and bm12 stimulators, which differ from respond-
ers only at three amino acids due to mutations in the IA re-
gion. T cells in the mAb treated had modestly reduced early
(day 2) proliferative responses as compared to the control




). However, proliferation in the control group
continued to increase, peaking on day 5–6 of culture, in con-
trast to T cells in the mAb-treated group, which decreased
throughout the evaluation period.
On day 10 of primary culture, cell recovery in the control
group was 90% and in the anti-CD40L mAb–treated group
11%, of input T cell number. T cells in the control and mAb-
treated groups had evidence of activation as denoted by for-




chain receptor; Fig. 2). As compared to the control group,
forward- and side-scatter profiles in the mAb-treated group
were consistently lower, albeit in both groups, an increased
forward- and side-scatter profile was observed as compared to
day 0 responder cells. In contrast, CD25 levels are typically
comparable in the mAb-treated and control groups. L-selectin
downregulation was more pronounced in the control group, a
 




consistent finding in all experiments analyzed to date. To de-
termine whether T cells in anti-CD40L mAb–treated cul-









 T cells from control or





The addition of exogenous IL-2 prevented the induction of





data indicate that the alloantigen hyporesponsiveness induced





 T cells in this culture system.
To assess the response of control or mAb-treated T cells to
alloantigen restimulation, day 10 MLR cells were washed to
remove mAb, and secondary MLR cultures were established.
Anti-CD40L mAb–treated T cells continued to be hypore-




). Responses of tolerized











 T cells have a markedly impaired
capacity to mediate GVHD lethality even with exogenous IL-2
supplementation in vivo.
 
To determine whether ex vivo toler-
ized T cells were impaired in inducing GVHD in vivo, a series
of experiments were performed in which various doses of con-





cells were infused into sublethally irradiated recipients bearing
the same alloantigen used as stimulator cells in MLR cultures.








 control cultured T cells were lethal to 97%





unable to cause lethality in any of the recipients of anti-CD40L
mAb–treated cells.
Because IL-2 can prevent anergy induction and anergic
cells will respond to alloantigen in the presence of exogenous
IL-2, cohorts of recipients of control or anti-CD40L mAb were
given IL-2 at a dose of 50,000 IU on Monday through Friday
from days 0–14 after transfer. Recipients of control cultured
cells, including those receiving IL-2 injections, all died by day
22 after transfer (Fig. 4). In contrast, 100% of recipients of
anti-CD40L mAb–treated cells and 80% of IL-2–treated re-




T cell–mediated GVHD–induced aplasia, hematocrit values
were assessed in all mice on day 14 (15) (Table I). Day 14
mean hematocrit values were significantly lower in recipients
of control cells than recipients of ex vivo tolerized cells,
Figure 1. Induction of alloantigen hyporesponsiveness in anti-CD40L mAb–treated cultures (A and C) and restoration of alloantigen responses 
by exogenous IL-2 (B and D). Primary MLR cultures (A and B) consisted of C57BL/6 CD41 lymph node T cell responders and bm12 splenic 
stimulators. After 10 d of primary culture, secondary MLR cultures were established (C and D). On the y-axis are mean cpm61 SD of the mean. 







whether or not recipients were also given exogenous IL-2. Re-








 2 mo after transfer, re-
gardless of whether or not mice also received IL-2. All mice
that received control cultured cells died before day 28 and,
therefore, were not analyzable for hematocrit values. These
data indicate that the tolerant state of anti-CD40L mAb–
treated cells is not readily reversed in vivo by exogenous IL-2.
 




 T cells persist in vivo.
 
As a rigor-





 T cells, T cells from control, and anti-CD40L mAb–
treated 10-d MLR cultures were parked in SCID mice that
were syngeneic to the donor (responder) strain. Because SCID
mice do not produce their own T cells, all T cells isolated from
these recipients are of donor origin. After 40 d, thoracic duct
lymphocytes from both groups of recipients were collected
overnight from the recirculating pool and the number of lym-
phocytes quantified (12, 15). As compared to the input num-





retrieved from recipients of control cultured cells. In recipients
of anti-CD40L mAb–treated cells, 45% of the input cells were




 T cells from recipients of control
Figure 2. Flow cytometry analysis of day 10 MLR cul-
tured cells. Primary MLR cultures from Fig. 1 A were 
analyzed on day 10 for evidence of T cell activation. 
Flow cytometry was performed to determine forward- 
(FSC) and side- (SSC) scatter contours as a measure-
ment of activation according to size and granularity 
characteristics. Overlay histograms are shown with 
the dotted line representing T cells from control cul-
tures and the bold line, CD41 T cells from the anti-
CD40L mAb–treated culture. Three color flow cy-
tometry was performed to determine the proportion 
of CD41 T cells that coexpressed CD25 or L-selectin 
(L-sel) and 7-AAD (a marker of early apoptosis). 
The percent of CD41 T cells coexpressing the indi-
cated determinant is listed in the upper right hand 
quadrant.
 




and anti-CD40L mAb–treated cells had similar flow cytomet-





duct lymphocytes from B6-SCID recipients of control or anti-
CD40L mAb–treated day 10 MLR cells had evidence of prior
activation as determined by forward- and side-scatter profiles,
downregulation of L-selectin, and upregulation of CD44 anti-
gen density, although CD25 was not upregulated (Table II).
These data are consistent with the generation of a memory cell
phenotype and the in vivo persistence of T cells from an ex
vivo tolerized culture.




 T cells from both
groups was assessed by adoptive transfer into sublethally irra-
diated secondary recipients (Fig. 5). All recipients of control
T cells uniformly succumbed to GVHD-induced lethality,
whereas none of the recipients of an equal number of anti-





 T cells exposed ex vivo to anti-CD40L
mAb can survive long term in SCID recipients, and the toler-







 T cell responses to nominal antigen responses are
preserved during ex vivo tolerization to alloantigen.
 
A culture
system was established in which T cell responses to an antigen
not present during the tolerization process could be accurately
quantified. To optimize quantification, we physically tracked




 T cells that
have the appropriate TCR for a vigorous response to the nom-




 T cell cultures contained 25%





 T cells of the same genetic (BALB/c) background. B6
stimulator cells differed from the responders at MHC class I
plus II loci, as well as several minor histocompatibility loci.
Figure 3. B6 anti-bm12-d 10 MLR cells 
cultured in the presence of anti-CD40L 
mAb do not cause GVHD lethality in sub-
lethally irradiated bm12 recipients. Control 
or anti-CD40L mAb–treated CD41 T cells 
were injected into bm12 recipients. CD41 T 
cell doses for recipients of control cells 
were: 3 3 105 (n 5 16), 105 (n 5 24), or
0.3 3 105 (n 5 16); doses for anti-CD40L 
mAb–treated cultures were: 10 3 105 (n 5 
3), 3 3 105 (n 5 16); 105 (n 5 22), or 0.3 3 
105 (n 5 16). Data are pooled from four 
replicate experiments. On the x-axis are 
days post-transfer. On the y-axis is the pro-
portion of recipients surviving post-trans-
fer. Recipients of anti-CD40L mAb treat-
ment had a significantly higher survival 
rate as compared to recipients of a compa-
rable number of control cultured cells at 
each cell dose tested.
Figure 4. IL-2 administration in vivo does 
not readily break the impaired GVHD ca-
pacity of anti-CD40L mAb–treated day 10 
MLR cells. Control or anti-CD40L mAb–
treated primary MLR cultured cells were 
injected into sublethally irradiated recipi-
ents (n 5 5 per group). Cohorts of mice, as 
indicated, received IL-2 injections at a dose 
of 50,000 IU on Monday through Friday 
from days 0–14 post-transfer. On the x-axis 
are days post-transfer. On the y-axis is the 
proportion of recipients surviving post-
transfer. As compared to controls receiving 
the same numbers of CD41 T cells, recipi-
ents of anti-CD40L mAb had a signifi-
cantly higher actuarial survival rate.
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Anti-CD40L mAb treatment induced alloantigen hypore-
sponsiveness in primary (Fig. 6 A) MLR cultures. Anti-CD40L
mAb–induced alloantigen hyporesponsiveness was prevented
by the addition of exogenous IL-2 (data not shown). To deter-
mine whether inhibition of alloantigen responses occurred at
the expense of nominal antigen responses, secondary cultures
were established to monitor alloantigen and nominal antigen
responses. Because the proportion of TCR transgenic CD41 T
cells was higher in the control as compared to the mAb-treated
group (36% versus 16%, respectively), the culture was ad-
justed such that the control and anti-CD40L mAb–treated cul-
tures contained the same number of non-transgenic CD41 T
cells per well for measuring alloresponses and the same num-
ber of transgenic CD41 T cells for measuring OVA responses.
Secondary MLR cultures in this strain combination were per-
formed on day 8 rather than day 10 to ensure that sufficient
numbers of transgenic and non-transgenic T cells were avail-
able for analysis. At the end of 8 d, cell recovery in the control
group was 158% and, in the anti-CD40L mAb–treated group,
28% of input T cell number. Anti-CD40L mAb treatment lead
to secondary alloantigen hyporesponsiveness (Fig. 6 B) as pre-
viously noted. Due to the earlier time period of primary cul-
ture, secondary responses to alloantigen-bearing stimulator
cells peaked on day 1 of secondary culture, a reproducible
finding in this and the B6 anti-bm12 system when cultures are
analyzed on day 8 rather than day 10 (our unpublished data).
Although 8 d are sufficient to tolerize alloreactive T cells to
host alloantigen-bearing stimulators ex vivo and to markedly
inhibit GVHD lethality in vivo, the longer 10-d culture system
results in a secondary MLR response that peaks later than ob-
served with 8-d cultures (unpublished data). The addition of
exogenous IL-2 facilitated effective T cell responses to alloan-
tigen in secondary cultures (data not shown). Importantly,
anti-CD40L mAb did not impair responses to OVA challenge
in secondary culture under conditions that were sufficient for
inducing alloantigen hyporesponsiveness after primary culture
(Fig. 6 C).
Discussion
In this study, we have shown that an ex vivo tolerization ap-
proach can be used to prevent GVHD lethality mediated by
MHC class II alloantigen-responsive CD41 T cells. Donor
CD41 T cells exposed ex vivo to host alloantigens in the pres-
ence of anti-CD40L mAb were rendered hyporesponsive to
host alloantigen as assessed in both primary and secondary
MLR culture. Ex vivo tolerized T cells were incapable of caus-
ing GVHD in vivo. Despite effective alloantigen tolerization,
nominal antigen responses remained intact. Tolerance was
long lived and not readily reversible by exogenous IL-2.
An interesting aspect of the present studies is the high de-
gree of GVHD protection afforded by ex vivo as compared to
in vivo anti-CD40L mAb exposure in this same strain combi-
nation. In previous studies, we have shown that sublethally ir-
radiated bm12 recipients of 105 CD41 T cells given anti-
CD40L mAb in vivo for up to 1 mo after transfer had a 55%
survival rate, corresponding to an approximate threefold re-
duction in GVHD-induced lethality. In contrast, our ex vivo
results described in the present report show a . 30-fold reduc-
tion in GVHD capacity of CD41 T cells exposed ex vivo to
bm12 alloantigen-bearing stimulator cells in the presence of
anti-CD40L mAb. The high degree of GVHD protection con-
ferred by ex vivo anti-CD40L mAb treatment cannot be ac-
counted for by a decreased GVHD lethality capacity of cul-
Table I. Effect of Exogenous IL-2 Administration or
GVH-induced Aplasia of Control or Anti-CD40L
mAb–treated Day 10 MLR Cultured cells Transferred into 
Sublethally Irradiated Recipients*
Day 10 MLR cells IL-2 Day Hematocrit
Control None 14 2461
Control Yes 14 2163
Anti-CD40L mAb None 14 4262‡
Anti-CD40L mAb Yes 14 3761‡
None Yes 14 4461‡
*Sublethally irradiated bm12 recipients (n 5 5/group) were given day 10
MLR cultured cells that were control cultured or treated with anti-
CD40L mAb. 105 cells were infused per group. Cohorts of mice were
given exogenous IL-2 at a dose of 50,000 IU i.p. on days 0–4 and days
7–11 after transfer. ‡P , 0.001, as compared to recipients of control cul-
tured cells.
Table II. Recovery and Flow Cytometry Analysis of Thoracic Duct Lymphocytes Isolated 40 d after Parking Control or
Anti-CD40L mAb–treated 10 d MLR Cultured Cells into B6-SCID Recipients*
Group % CD4
CD41 T cells CD41
per mouse 3 106 FSC SSC % CD25 % L-selectin % CD44 7-AAD
Control cultured 79 3.7 364 286 4 11 77 (734) 1
Anti-CD40L mAb 63 0.9 354 268 5 16 62 (629) 1
B6 controls 31 12.4 307 186 3 32 24 (154) 0
*Primary MLR cultures were established using highly purified lymph node CD41 T cells from B6 mice as responders and irradiated, T cell depleted
bm12 splenic stimulators. At the end of 10 d, cells were infused into sublethally irradiated bm12 recipients (0.3–10 3 105/mouse) (see Fig. 2) or B6-
SCID mice (2 3 106/mouse). After 40 d, thoracic duct lymphocytes were isolated from B6-SCID mice or non-BMT B6 controls (n 5 5/group) during
an overnight collection period. The number of thoracic duct lymphocytes was quantified and data normalized for a 24-h period. Flow cytometry was
performed to determine CD41 T cell content and values used to calculate the total number of CD41 T cells produced in 24 h. Forward- (FSC) and side-
(SSC) scatter contour plots of CD41 T cells were acquired as a measurement of activation according to size and granularity. Three color flow cytome-
try was performed to determine the percent of cells that coexpressed CD4 and CD25 (activation marker), memory cell markers (L-selectinlo, CD44hi)
or 7-AAD (a marker of early apoptosis). The numbers shown in ( ) are the mean fluorescent channel for quantifying CD44 antigen density.
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tured cells, as few as 0.3 3 105 CD41 T cells resulted in 95%
lethality when transferred into sublethally irradiated recipi-
ents, similar to results we have observed with fresh CD41 T
cells in this system.
It is possible that the superior survival results obtained with
ex vivo as compared to in vivo anti-CD40L mAb are due to a
prolonged continuous exposure of CD41 T cells to mAb en-
sured by ex vivo culture. In support of this hypothesis, we have
observed that the tolerization of CD41 T cells to MHC class II
alloantigens is not complete by 4 d of culture (our unpublished
data). Because CD40L is only transiently expressed on acti-
vated CD41 T cells (6), the availability of saturating concentra-
tions of anti-CD40L mAb for a prolonged period of time ex
vivo may increase the probability that all T cells that can re-
spond to alloantigen do so in the presence of blocking concen-
tration of anti-CD40L mAb. In vivo, mAb may not be immedi-
ately available at the time and site of T cell activation to
downregulate the response.
The quality of the in vitro alloresponse in the bulk culture
may differ from that observed in vivo. For example, donor T
cells might recognize host MHC antigens that are processed by
donor APC and presented in the context of donor MHC mole-
cules, a process known as indirect allorecognition (18–22; re-
viewed in 23). Alternatively, donor T cells may directly recog-
nize host alloantigen-bearing cells, a process known as direct
allorecognition. The predominant APC in vivo would by ne-
cessity be host-derived, as purified donor T cells containing
few donor APC were infused in vivo in our initial experiments
in which anti-CD40L mAb was infused in vivo and in the
present studies using ex vivo tolerized T cells. Because of the
paucity of donor APC that would be available to encounter
donor T cells in vivo, the in vivo GVHD response in this suble-
thal TBI system likely would involve direct and not indirect al-
lorecognition. Although purified donor T cells are used as re-
sponders, the ex vivo bulk culture system theoretically would
offer a greater opportunity for indirect allorecognition because
the few remaining APC present in the purified donor T cell
population could permit indirect allorecognition to occur.
Conceivably, the ease to which tolerization to host alloanti-
gens is achieved could be due to the type of allorecognition
such that tolerization might be more readily obtained via an in-
direct rather than a direct allorecognition pathway. Tolerance
to the dominant antigenic determinants presented via the indi-
rect allorecognition pathway in fact has been shown to be re-
quired to prevent amplification and perpetuation of organ
graft rejection (22). However, the predominant APC in the ex
vivo cultures would be of host origin and few, if any, functional
donor APC would be present using these highly purified T cell
responders. Moreover, the requirement for the indirect al-
lorecognition pathway in the ex vivo tolerization culture sys-
tem is unclear and the frequency of T cells capable of using the
indirect pathway is lower (z 100-fold lower to HLA-DR) (19).
Although it is formally possible that the superior GVHD pro-
tective effects obtained with ex vivo as contrasted to in vivo
anti-CD40L mAb could be due to a greater dependency of the
indirect rather than the direct pathway for allorecognition, this
hypothesis seems unlikely.
It is also possible that anti-CD40L mAb may have skewed
CD41 T cells away from a Th-1 phenotype. Data from several
investigators have shown that the ex vivo generation of skew-
ing of CD41 T cells away from a T helper type 1 (Th-1: IL-2,
interferon gamma producing) cytokine phenotype is an effec-
tive means of preventing GVHD lethality (e.g., 24, 25). Al-
though control cultured cells have a Th-1 phenotype, anti-
CD40L mAb–treated CD41 T cells produce markedly lower
amounts of Th-1 cytokines (our unpublished data). These data
are consistent with our previous findings that in vivo anti-
CD40L mAb treatment of allogeneic BMT recipients inhibits
the generation of CD41 T cells with a Th-1 phenotype (12).
The protective effect of anti-CD40L mAb ex vivo also does
not appear to be due to skewing toward a T helper type 2
(Th-2: IL-4 producing) cytokine production since CD41 T cells
Figure 5. Ex vivo anti-CD40L mAb–
treated day 10 MLR cultured cells have a 
long-lasting impairment in their capacity to 
mediate GVHD lethality. Control or anti-
CD40L mAb–treated CD41 T cells were 
injected into non-irradiated C57BL/
6-SCID mice 40 d before thoracic duct can-
nulation. Thoracic duct lymphocytes from 
recipients of control or anti-CD40L mAb–
treated primary MLR cultured cells were 
injected at a dose of 105 CD41 T cells per 
mouse into sublethally irradiated second-
ary recipients (n 5 5 per group). On the
x-axis are days post-transfer. On the y-axis 
is the proportion of recipients surviving 
post-transfer. Recipients of anti-CD40L 
mAb–treated cells parked for 40 d had a 
significantly higher actuarial survival rate 
as compared to recipients of control cul-
tured cells parked for 40 d.
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from IL-4 knockout (Th-2 deficient) mice were susceptible to
ex vivo anti-CD40L mAb induced tolerization (our unpub-
lished data).
Although anti-CD40L mAb may have altered the capacity
of T cells to respond to alloantigen, it is possible that anti-
CD40L mAb treatment resulted in a high degree of cell death.
Cell recovery was consistently lower in anti-CD40L mAb–
treated cultures. However, anti-CD40L mAb treatment did
not lead to an increased frequency of cells undergoing early
apoptosis as measured by 7-AAD staining (17) either at the
end of the culture or at intervals during the culture period.
Anti-CD40L mAb treatment of MLR cultures ex vivo did not
preclude the in vivo maintenance of the majority of CD41 T
cells infused into syngeneic SCID recipients as one-half of
CD41 T cells exposed to anti-CD40L mAb ex vivo and rested
(parked) in B6-SCID mice were retrievable later by thoracic
duct cannulation. Sprent et al. have observed that approxi-
mately equal numbers of naive T cells parked in syngeneic
SCID mice are retrievable after a period of . 1 mo (26). Fu-
ture experiments designed to track TCR transgenic alloreac-
tive T cells will be required to determine whether deletion/cell
death, failure of clonal expansion, or a functional alteration
(tolerization) of T cells is the primary mechanism responsible
for the lack of GHVD lethality observed after the ex vivo ex-
posure to anti-CD40L mAb.
An important aspect of our studies was the demonstration
that anti-CD40L mAb–induced tolerance was long lasting. Af-
ter 40 d of parking in vivo, control but not tolerized cells were
capable of causing GVHD. Thus, a long-lived state of toler-
ance was maintained. Although IL-2 in high concentrations
(50 U/ml) that cannot be sustained in vivo post-BMT (27)
could prevent or reverse the generation of tolerized cells, IL-2
administration even at dose of 50,000 IU/dose given intraperi-
toneally in vivo could not readily induce GVHD by tolerized
cells. Collectively, these data would suggest that TCR trigger-
ing by environmental antigens, infectious agents, or tumor an-
tigens even early after transfer are not likely to cause GVHD
by the provision of exogenous IL-2.
It was important to determine whether immune responses
of T cells not involved in the GVHD response were intact.
GVHD prevention by ex vivo anti-CD40L mAb was not due
to the global immune suppression of both relevant alloantigen-
responsive cells and bystander (no anti-host alloreactive po-
tential) cells. By seeding TCR transgenic T cells in a MLR cul-
ture containing wild-type CD41 T cells and alloantigen, we
have shown that anti-host hyporesponsiveness can be achieved
as assessed in both primary and secondary MLR cultures with-
out causing bystander cell inhibition as assessed by quantifying
the response of OVA-responsive TCR transgenic cells to
OVA nominal antigen. The fact that nominal antigen re-
Figure 6. Anti-CD40L mAb treatment in BALB/c anti-B6 primary 
MLR cultures inhibits B6 alloantigen responses without affecting nomi-
nal antigen responses. Non-transgenic BALB/c CD41 T cells were com-
bined with D011.10 (BALB/c) CD41 TCR transgenic T cells in a ratio 
of 3:1, and then added to C57BL/6 splenic stimulator cells in the pres-
ence or absence of anti-CD40L mAb (A). For secondary MLR re-
sponses, an equal number of non-transgenic BALB/c CD41 T cells 
from day 8 control or anti-CD40L mAb–treated cultures were plated in 
secondary MLR cultures with B6 splenic stimulators (B). For OVA re-
sponses, an equal number of D011.10 TCR transgenic CD41 T cells 
from day 8 control or anti-CD40L mAb–treated cultures were plated 
with irradiated BALB/c splenocytes as feeder cells. (C) OVA peptide
(5 mg/ml) or no peptide (data not shown) was added to each well. On 
the y-axis are mean cpm61 SD of the mean. On the x-axis are days in 
culture. Mean CPM values for wells containing no peptide were , 750 
at all time points in both groups. A representative experiment is shown. 
Findings were reproduced in a second experiment.
Murine Graft-Versus-Host Disease Prevention by Ex Vivo CD40 Ligand:CD40 Blockade 481
sponses remain intact during the tolerization process suggests
that the anti-viral or anti-leukemia responses of alloantigen
nonresponsive cell populations may be preserved. In that
event, ex vivo tolerization would have an advantage compared
to ex vivo approaches, which rigorously deplete T cells or in
vivo approaches, which globally immunosuppress the recipient.
Although D011.10 CD41 thymic T cells are capable of re-
sponding to B6 alloantigens in vivo because these cells are neg-
atively selected in B6 mice (28), we do not favor the explana-
tion that the B6 alloresponse in the primary culture decreased
the threshold for OVA responses of the tolerized T cells in
secondary culture for several reasons. First, D011.10 CD41 T
cells do not appear to have been activated in primary culture
in the anti-CD40L mAb–treated group based upon low CD25
expression in the mAb-treated versus control group (7.5%
versus 38% of CD41 KJ1–261 cells, respectively) and lower
forward- (335 versus 460) and side- (156 versus 280) scatter
contours. D011.10 CD41 T cells in the mAb-treated group
were not entirely quiescent as CD62L (L-selectin) was down-
regulated on the transgenic T cells to a similar extent in both
the control and mAb-treated groups (20% versus 16%). How-
ever, even if the D011.10 CD41 T cells in the control cultures
were activated directly rather than indirectly by B6 alloanti-
gens, the mAb-treated cells would have been significantly less
activated, such that a lower OVA response using tolerized
cells might have been expected. Second, in the absence of
OVA in secondary cultures, the proliferative response of
D011.10 CD41 T cells is low using T cells obtained from either
group such that the stimulation index to OVA (response to
OVA divided by response in absence of OVA) was . 30 at all
time points. Thus, although we formally cannot exclude the
possibility that a small subset of D011.10 that have responded
to B6 alloantigens has not been tolerized and that this subset
contributes to the OVA response when using T cells obtained
from the anti-CD40L mAb–treated cultures, B6 alloantigen
responsiveness by D011.10 CD41 T cells does not appear to be
a major contributing factor to the observed preservation of
OVA responses in secondary cultures.
In summary, the present experiments provide the first for-
mal demonstration that T cells cultured ex vivo with host al-
loantigen-bearing stimulator cells can enter a state of long-
lived antigen-specific tolerance that is not readily reversible in
vivo and that does not impair nominal antigen responses.
These data suggest that beneficial CD41 T cell responses that
support the generation of anti-leukemia (29) or anti-viral ef-
fector cells may be preserved. Because CD41 T cell number
and function return slowly after bone marrow transplantation
(30, 31) especially in adults, the repetitive infusion of large
numbers of CD41 T cells incapable of causing GVHD may be
useful in supporting the recipient until T cell reconstitution oc-
curs. If shown to be the case in humans, this strategy would of-
fer a clear advantage to currently available approaches that are
associated with prolonged periods of immune reconstitution,
especially in the adult recipient.
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